BACKGROUND: Vitamin D plays a protective role in ulcerative colitis (UC) patients through unclear mechanisms. Cathelicidin is an antimicrobial peptide induced by 1,25(OH)D2. Our goal was to evaluate the link between cathelicidin and vitamin D-associated clinical outcomes in UC patients, explore vitamin D induction of cathelicidin in human colon cells, and evaluate the effects of intrarectal human cathelicidin on a murine model of colitis. METHODS: Serum and colonic cathelicidin levels were measured in UC patients and correlated with clinical and histologic outcomes. Human colon cells were treated with 1,25(OH)2D and production of cathelicidin and cytokines were quantified. Antimicrobial activity against Escherichia coli from cell culture supernatants was measured. Mice were treated with intrarectal cathelicidin, and its effects on DSS colitis and intestinal microbiota were evaluated. RESULTS: In UC patients, serum 25(OH)D positively correlated with serum and colonic cathelicidin. Higher serum cathelicidin is associated with decreased risk of histologic inflammation and clinical relapse but not independent of 25(OH)D or baseline inflammation. The 1,25(OH)2D treatment of colon cells induced cathelicidin and IL-10, repressed TNF-α, and suppressed Escherichia coli growth. This antimicrobial effect was attenuated with siRNA-cathelicidin transfection. Intrarectal cathelicidin reduced the severity of DSS colitis but did not mitigate the impact of colitis on microbial composition. CONCLUSIONS: Cathelicidin plays a protective role in 25(OH)D-associated UC histologic outcomes and murine colitis. Cathelicidin is induced by vitamin D in human colonic epithelial cells and promotes antimicrobial activity against E. coli. Our study provides insights into the vitamin D-cathelicidin pathway as a potential therapeutic target.
BACKGROUND:Vitamin D plays a protective role in ulcerative colitis (UC) patients through unclear mechanisms. Cathelicidin is an antimicrobial peptide induced by 1,25(OH)D2. Our goal was to evaluate the link between cathelicidin and vitamin D-associated clinical outcomes in UCpatients, explore vitamin D induction of cathelicidin in human colon cells, and evaluate the effects of intrarectal human cathelicidin on a murine model of colitis. METHODS: Serum and colonic cathelicidin levels were measured in UCpatients and correlated with clinical and histologic outcomes. Human colon cells were treated with 1,25(OH)2D and production of cathelicidin and cytokines were quantified. Antimicrobial activity against Escherichia coli from cell culture supernatants was measured. Mice were treated with intrarectal cathelicidin, and its effects on DSS colitis and intestinal microbiota were evaluated. RESULTS: In UCpatients, serum 25(OH)D positively correlated with serum and colonic cathelicidin. Higher serum cathelicidin is associated with decreased risk of histologic inflammation and clinical relapse but not independent of 25(OH)D or baseline inflammation. The 1,25(OH)2D treatment of colon cells induced cathelicidin and IL-10, repressed TNF-α, and suppressed Escherichia coli growth. This antimicrobial effect was attenuated with siRNA-cathelicidin transfection. Intrarectal cathelicidin reduced the severity of DSS colitis but did not mitigate the impact of colitis on microbial composition. CONCLUSIONS: Cathelicidin plays a protective role in 25(OH)D-associated UC histologic outcomes and murinecolitis. Cathelicidin is induced by vitamin D in human colonic epithelial cells and promotes antimicrobial activity against E. coli. Our study provides insights into the vitamin D-cathelicidin pathway as a potential therapeutic target.
Authors: Hon Wai Koon; David Q Shih; Jeremy Chen; Kyriaki Bakirtzi; Tressia C Hing; Ivy Law; Samantha Ho; Ryan Ichikawa; Dezheng Zhao; Hua Xu; Richard Gallo; Paul Dempsey; Genhong Cheng; Stephan R Targan; Charalabos Pothoulakis Journal: Gastroenterology Date: 2011-07-14 Impact factor: 22.682
Authors: Teizo Yoshimura; Mairi H McLean; Amiran K Dzutsev; Xiaohong Yao; Keqiang Chen; Jiaqiang Huang; Wanghua Gong; Jiamin Zhou; Yi Xiang; Jonathan H Badger; Colm O'hUigin; Vishal Thovarai; Lino Tessarollo; Scott K Durum; Giorgio Trinchieri; Xiu-Wu Bian; Ji Ming Wang Journal: J Immunol Date: 2018-02-12 Impact factor: 5.422
Authors: Olof Hertting; Åsa Holm; Petra Lüthje; Hanna Brauner; Robert Dyrdak; Aino Fianu Jonasson; Peter Wiklund; Milan Chromek; Annelie Brauner Journal: PLoS One Date: 2010-12-14 Impact factor: 3.240
Authors: Jun Hwan Yoo; Samantha Ho; Deanna Hoang-Yen Tran; Michelle Cheng; Kyriaki Bakirtzi; Yuzu Kukota; Ryan Ichikawa; Bowei Su; Diana Hoang-Ngoc Tran; Tressia C Hing; Irene Chang; David Q Shih; Richard E Issacson; Richard L Gallo; Claudio Fiocchi; Charalabos Pothoulakis; Hon Wai Koon Journal: Cell Mol Gastroenterol Hepatol Date: 2015-01
Authors: Jiani Wang; Michelle Cheng; Ivy K M Law; Christina Ortiz; Mingjun Sun; Hon Wai Koon Journal: Mol Ther Oncolytics Date: 2019-01-29 Impact factor: 7.200
Authors: Cristiano Pagnini; Andrea Picchianti-Diamanti; Vincenzo Bruzzese; Roberto Lorenzetti; Michele Maria Luchetti; Louis Severino Martin Martin; Roberta Pica; Palma Scolieri; Maria Lia Scribano; Costantino Zampaletta; Maria Sole Chimenti; Bruno Lagana Journal: Int J Mol Sci Date: 2021-02-28 Impact factor: 5.923
Authors: Carolina Battistini; Rafael Ballan; Marcos Edgar Herkenhoff; Susana Marta Isay Saad; Jun Sun Journal: Int J Mol Sci Date: 2020-12-31 Impact factor: 5.923
Authors: Emily C Sanders; Robert M Burkes; Jason R Mock; Todd T Brown; Robert A Wise; Nadia N Hansel; Mark C Liu; M Bradley Drummond Journal: Chronic Obstr Pulm Dis Date: 2021-07-28